# DESCRIPTION

## BACKGROUND

- introduce HIV detection
- describe limitations of current detection methods
- motivate need for new compositions and assays
- describe importance of anti-gp41 antibodies
- highlight challenges of current diagnostic tests

## SUMMARY

- introduce protein-catalyzed capture agents (PCC Agents)
- describe methods for making PCC Agents
- describe assays employing PCC Agents
- highlight thermal stability of compositions

## Anchor Ligand

- describe anchor ligand composition

### Secondary Ligand

- describe secondary ligand selection
- provide examples of secondary ligands

### Tertiary and Quaternary Ligands

- describe tertiary and quaternary ligand selection

### Triazole Linkage

- describe triazole linkage formation
- provide examples of triazole linkages

### Bilagands, Triligands and Tetraligands

- describe biligand, triligand, and tetraligand structures
- provide examples of biligands, triligands, and tetraligands

### Properties

- describe stability properties of capture agents

### Detectable Labels

- describe detectable labels for capture agents

## Methods and Uses

- describe method of diagnosing HIV infection
- describe method of detecting anti-gp41 antibodies
- describe use of capture agents for diagnosis
- describe method of detecting anti-gp41 antibodies in immunoassay
- describe method of monitoring treatment of HIV infection
- describe kit for detecting anti-gp41 antibodies

### Kits

- describe kit components
- describe kit instructions
- describe optional kit components

## Synthesis of Capture Agents

- describe method of making capture agents
- describe anchor ligand selection
- describe secondary ligand selection
- describe tertiary ligand selection
- describe quarternary ligand selection
- describe multiplex capture agent composition

## DETAILED DESCRIPTION

- disclaim limitations
- define terminology

### DEFINITIONS

- define amino radical
- define cyano radical
- define hydroxy radical
- define imino substituent
- define nitro radical
- define oxo substituent
- define thioxo substituent
- define alkyl radical
- define alkylene chain
- define alkoxy radical
- define aminocarbonyl radical
- define alpha-amino carbonyl radical
- define alpha-amido carbonyl radical
- define alkylamino radical
- define thioalkyl radical
- define aryl radical
- define aralkyl radical
- define cycloalkyl radical
- define cycloalkylalkyl radical
- define fused ring structure
- define halo or halogen radical
- define haloalkyl radical
- define heterocyclyl radical
- define N-heterocyclyl radical
- define heterocyclylalkyl radical
- define heteroaryl radical
- define N-heteroaryl radical
- define heteroarylalkyl radical
- define substituted groups
- describe substituted groups with non-hydrogen atoms
- describe substituted groups with higher-order bonds
- define prodrug
- describe prodrug conversion in vivo
- describe isotopically-labelled compounds
- define invention scope
- introduce metabolic products
- define mammal
- define optional
- define pharmaceutically acceptable carrier
- define pharmaceutically acceptable salt
- define asymmetric centers
- introduce stereoisomers
- define tautomer
- introduce solvate
- define capture agent
- define epitope
- define polypeptide
- define amino acid
- define non-natural amino acid
- define specific binding
- define KD
- define kd
- define ka
- define KA
- define pharmaceutical composition
- define condition
- define treat
- define effective amount
- define antibody
- define stable
- define synthetic
- introduce BLAST
- introduce low-complexity filters
- define sequence identity
- define sequence similarity
- define percentage of sequence identity
- define substantial identity
- introduce gp41
- define HIV-1 gp41 protein
- introduce anchor ligand
- define anti-gp41 antibodies
- introduce epitope targeting
- define capture agent binding
- define dissociation equilibrium constant
- define association rate constant
- define association equilibrium constant
- introduce pharmaceutical formulation
- define therapeutically effective amount
- conclude definitions

### Development of Anti-Gp41 Antibody Capture Agents

- motivate replacement of antibodies
- describe limitations of antibodies
- introduce in situ click chemistry
- describe sequential in situ click chemistry
- apply sequential in situ click chemistry to anti-gp41 antibodies
- describe product screens
- summarize capture agent generation
- describe capture agent properties
- describe capture agent stability
- describe capture agent shelf-life

### Anti-Gp41 Antibody Capture Agents

- introduce biligand capture agents
- describe anchor and secondary ligands
- describe target-binding moieties
- describe covalent linkages
- describe Tz4 and Tz5 linkages
- describe tertiary and quarternary ligands
- describe amide bond formation
- describe capture agent stability
- describe capture agent shelf-life
- describe detection labels
- describe modification of capture agents
- describe cyclizing capture agents
- describe modifying synthesis blocks

### Methods of Making/Screening Capture Agents

- introduce capture agent production methods
- describe identifying anchor ligands
- describe identifying secondary ligands
- describe identifying tertiary ligands
- describe identifying quarternary ligands
- describe omitting steps
- describe using known anchor ligands
- describe using OBOC peptide libraries
- describe modifying anchor ligands
- describe screening/preparation process
- describe synthesizing capture agents
- describe preparing synthesis blocks
- describe coupling synthesis blocks

### Methods for Targeting Specific Antibodies

- introduce approach for synthesizing molecules
- describe preparing peptide or polypeptide fragments
- describe modifying polypeptide fragments
- describe incubating with molecular library
- describe identifying hit molecules
- describe increasing affinity and specificity

### In Vitro

- describe in vitro detection of anti-gp41 antibodies
- describe fluorescently labeled capture agents
- describe sandwich-type ELISA assays

### Diagnostic Imaging

- introduce capture agents for diagnostic imaging
- describe conjugating capture agents with labels

### Therapeutic Applications

- introduce antibody capture agents
- describe immunoassay methods
- define biological sample types
- diagnose HIV infections
- link therapeutic agents to capture agents
- fuse capture agents to therapeutic proteins
- provide example illustrations

## EXAMPLES

### Example 1

- introduce antibody-targeted PCC development
- describe anchor peptide design
- detail in situ click screen process
- explain target IgG detection
- describe biligand synthesis
- detail affinity measurement using sandwich ELISA
- describe surface plasmon resonance (SPR) assay
- summarize results of PCC agent development

### Example 2

- evaluate antibody-targeting peptides
- describe immunoprecipitation assays
- detail Western blotting detection
- explain sandwich ELISA and SPR assays
- describe biligand performance evaluation
- compare PCC agent cocktail to commercial chimeric antigen
- detail thermal stability testing
- describe HPLC analysis
- summarize results of biligand evaluation

### Example 3

- describe anchor synthesis
- detail OBOC screen process
- summarize anchor peptide purification

### Example 4

- describe screening against 3D6
- detail preclear step
- explain target screen step
- describe anti-screen step
- detail product screen step
- summarize screening results

### Example 5

- describe screening against 4B3

### Example 6

- describe biligand synthesis
- detail Pra-OtBu synthesis
- explain peptide synthesis
- describe click reaction
- detail anchor component synthesis
- describe cyclization reaction
- summarize peptide purification
- describe scaling up of peptide synthesis
- summarize biligand synthesis results

### Example 7

- describe anchor binding ELISA

### Example 8

- describe surface plasmon resonance

### Example 9

- prepare biotinylated chimera
- saturate streptavidin-coated plates
- block plates with milk
- incubate capture reagents with serum
- probe bound antibody with HRP-conjugated antibody
- develop colorimetric assay

